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Much ink has been wasted ove: the past year on the calcium 
antagonist controversy. It was initially triggered by a case- 
control study (1) and subsequently fueled by a meta-analysis 
(2) purporting to show that calcium antagonists as a class were 
harmful for the treatment of cardiovascular disorders and 
therefore should be used as third-line drugs, if at all. Panic 
among patients and frustration among physicians, mainly 
caused by inappropriate news media coverage, further added 
oil to the fire to the extent !hat the National Institutes of 
Health, the Food and Drug Administration (FDA) and Sidney 
Wolfe’s group of concerned citizens felt compelled to get 
involved. Indeed, it would be highly alarming if drugs that are 
given with the intention to lower the risk of heart attack; and 
strokes did paradoxically increase this risk. Such revelations 
stunned the academic community for quite some time until it 
became apparent that 1) there were serious llaws in the data 
purporting calcium antagonists to be cardiotoxic (3-7); and 2) 
the evidence stemmed from only short-acting calcium antago- 
nists that were used inappropriately. Not only were two of the 
three short-acting calcium antagonists not approved for the 
treatment of hypertension in the case-control study in ques- 
tion, but as Psaty recently conceded (Psaty BM. On record, 
FDA hearing, Bethesda, Matyland, January 1996), these drugs 
were given often once or twice a day, thereby leaving the 
patient’s blood pressure uncontrolled through a major part of 
a 24-h period. At best this regimen (i.e., nifedipine capsule 
given once or twice daily) will result in blood pressure control 
for a few hours only (“bungee” therapy). At worst, it will result 
b symptomatic hypotension, reflexive tachycardia and exces- 
sive sympathetic stimulation, thereby increasing the risk of 
myxdial ischetnia (Wilson DG, Schwa& GL, Textor SC, 
Zach &III PK, gheps SG. Unpublished observations, Septem- 
ber 1991). Such antihype&nsive therapy should ‘be regarded 
as clear deviation from accepted standards of medii practice, 
and it is little wonder that the outcome also deviated from 
these standa& A similar point can be made regarding the 
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meta-analysis of Furberg et at (2): Short-acting nifedipine has 
never been indicated in acute myocardial infarction. To the 
comrary, as we pointed out >5 years ago (It), it must be 
considered contraindicated in this situation. 
Over the past year, several sets of data attesting to the 
s+h, z. i elbcao of the long-acting calcium antagonists h:lve 
been presented (6). Although none of these studies m be 
considered definite evidence attesting to safety and efficacy in 
terms of mortality, they should allow physicians to feel more 
confident when prescribing calcium antagonists for proper 
indications. The study of Braun et al. (9) in this issue of the 
Journal is a case in point. It documents in a cohort study of 
>ll,OOtl patients who were randomized to receive either 
placebo or one of three different calcium antagonists ;dilti- 
axem, verapamil or nifedipine) that there was no association 
between calcium antagonists and mortality. It therefore argues 
against the allegations that calcium antagonists were harbii- 
gers of an increased mortality when used in patients with 
coronary artery disease. Of note, and in contrast to the study in 
a hypertensive population by Pahor et al. (lo), there was no 
significant difference in mortality among the three short-acting 
calcium antagonists. Two recent case-control studies further 
attest to the safety of long-acting calcium antagonists in 
hypertension. The findings of Aursnes et al. (11) indicated ihat 
the relative risk of acute myocardial infarction was lower in the 
calcium antagonist group than in any other treatment group. 
Speci&aUy, it was 50% the risk of standard theraa (i.e, 
beta-adrenergic blocking ,agents and diuretic drugs). Simihuly, 
a thoroughly conducted study from Harvard (12) reports the 
adjusted relative risk for acute myocardial infarction to be 
somewhat lower in the patient groups taking calcium antago- 
nists alone or calcium antagonists in combination with diuretic 
drugs compared with the group receiving beta-blocker mono- 
therapy. 
Clearly, none of these studies provides definite evidence of 
safety and elhcacy of the calcium antagonists in terms of 
morbidity and mortality. In this context, it must be remem- 
bered that this has been documented in hypertension for the 
diuretic drugs only and is lacking for all other drug classes, 
including the beta-blockers, angiotensin converting enzyme 
inhibitors, angiotensin receptor inhibitors, alpha-blockers and 
vasodilators. Calcium antagonists are by no means the only 
drug class for which safety has been questioned. Paradoxic 
increases in mortality have recently been reported for beta- 
blockers (13,14), diuretic drugs (13,14) and digitalis (15) but 
were not deemed to be newsworthy for the media. 
Reassuringly, after a 9-h hearing on January 2.5,1996, the 
FDA’s expert panel on cardiovascular drugs gave the long- 
acting and heart rate-lowering calcium antagonists a clean bill 
of health and urged the agency to enforce labeiing for nifedi- 
pine capsules that does not iachrde hypertemicm or unstable 
anghm (Xi). In addition, several randomixed, pmspe&e, 
multicenter (and muMmiMon dollar) studies are presently 
ongoing that within the next few years will shed some light, on 
the calciwm anmgonist and other contmversies. Until these 
0733-1097/%%1SM 
Pll sa73s-losy%)ulII7l-4 
JACC Vol. Zb, No. 1 MESSERLJ 13 
July 1996~12-3 zxTo,KAL coMYE?cf 
solid data become available, physicians, authors and editors 
are urged to restrain the flow of ink from this issue (17). 
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